Mergers & Acquisitions
By The Online Investor Staff, updated Thu., Mar. 28, 5:09 PM
This Slide: #71 of 100 |
Slide #71. Bristol Myers Squibb — Karuna Therapeutics
Acquirer:
Bristol Myers Squibb (NYSE:BMY)
Acquiree:
Karuna Therapeutics
Details:
PureTech Health plc (NASDAQ:PRTC,LSE,PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, today announced the completed acquisition of its Founded Entity, Karuna Therapeutics, Inc. ("Karuna"), by Bristol Myers Squibb (NYSE:BMY) ("BMS"), which has acquired all outstanding common stock of Karuna for $330.00 per share, for a total equity value of approximately $14 billion.
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s pharmaceutical products include chemically-synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor T-cell therapies. Co.'s primary product includes Eliquis® - Eliquis (apixaban), which is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
Bristol-Myers Squibb SEC Filing Email Alerts Service
Preferred: BMYMP
Open the BMY Page at The Online Investor »
|
Open the BMY Page at The Online Investor (in a new window) »
Free BMY Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Hold (2.30 out of 4) 0th percentile
(ranked lower than approx. 100% of all stocks covered)
Analysts' Target Price: BMY Stock Forecast Based on Zacks ABR data; powered by Xignite |